Offer extended until 31 July 2026: get a 10% early-bird discount on all events starting on or after 25 August 2026. To the promotion
GMP search engine – look up GMP compliance regulations and news
FDA Guidance Plans for 2026
Recommendation
1/2 December 2026
How to implement EU-GMP Chapter 8
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The FDA's Center for Drug Evaluation and Research (CDER) has released its list of guidance documents that it is considering for development during the 2026 calendar year. The list includes both new Level 1 draft guidance as well as previously issued Level 1 guidance that are planned to be revised.
According to the FDA, the document reflects the agency's current planning priorities. However, the list is not binding, and CDER is not required to issue all guidance included. The agency also retains the flexibility to develop additional guidance documents on topics that are not listed.
The list also contains some planned pharmaceutical quality guidance documents, like for example:
- PET Drugs - Current Good Manufacturing Practice (CGMP); Revised Draft
- Responding to Form FDA 483 Observations at the Conclusion of a Drug CGMP inspection
- AI and ML Quality Considerations in Pharmaceutical Manufacturing
- Container Closure Systems for Drugs, Including Biological Products
- Postapproval Changes to Drug Substances; Revised Draft
- Site Master Files
- Stability Considerations and Recommendations
Related GMP News
02.11.2026Singapore Added to the List of Recognised third Countries for Importation of APIs
02.11.2026Failed GMP Training in 2026: Further GMP Training Deficiencies in FDA Warning Letters
21.10.2026Switzerland: GMP Compliance by Foreign Manufacturers
14.10.2026EU Pharma Package: Council Adopts New Rules
14.10.2026ICH Publishes New Training Material for Quality Guidelines
14.10.2026WHO issues Draft Guidance on Quality Risk Management